1. Sirtuin-1 Activation Controls Tumor Growth by Impeding Th17 Differentiation via STAT3 Deacetylation
- Author
-
Romain Euvrard, Cédric Rébé, François Ghiringhelli, Hélène Berger, Emeric Limagne, Dominique Delmas, Frédérique Végan, Valentin Derangère, Marion Thibaudin, Lionel Apetoh, Sylvain Ladoire, Pauline Chalons, Etienne Humblin, Romain Boidot, Lipides - Nutrition - Cancer [Dijon - U1231] (LNC), Université de Bourgogne (UB)-AgroSup Dijon - Institut National Supérieur des Sciences Agronomiques, de l'Alimentation et de l'Environnement-Institut National de la Santé et de la Recherche Médicale (INSERM), Département d'oncologie médicale [Centre Georges-François Leclerc], Centre Régional de Lutte contre le cancer Georges-François Leclerc [Dijon] (UNICANCER/CRLCC-CGFL), UNICANCER-UNICANCER, Plateforme de transfert en biologie cancérologique [Dijon], Centre d'épidémiologie des populations (CEP), Université de Bourgogne (UB)-Centre Régional de Lutte contre le cancer Georges-François Leclerc [Dijon] (UNICANCER/CRLCC-CGFL), UNICANCER-UNICANCER-Université de Bourgogne (UB)-Centre Régional de Lutte contre le cancer Georges-François Leclerc [Dijon] (UNICANCER/CRLCC-CGFL), Lipides - Nutrition - Cancer [Dijon - U1231] ( LNC ), Université de Bourgogne ( UB ) -AgroSup Dijon - Institut National Supérieur des Sciences Agronomiques, de l'Alimentation et de l'Environnement-Institut National de la Santé et de la Recherche Médicale ( INSERM ), Centre Régional de Lutte contre le cancer - Centre Georges-François Leclerc ( CRLCC - CGFL ), Laboratoire Chrono-environnement ( LCE ), Université Bourgogne Franche-Comté ( UBFC ) -Centre National de la Recherche Scientifique ( CNRS ) -Université de Franche-Comté ( UFC ), Centre d'épidémiologie des populations ( CEP ), and Université de Bourgogne ( UB ) -Centre Régional de Lutte contre le cancer - Centre Georges-François Leclerc ( CRLCC - CGFL ) -Université de Bourgogne ( UB ) -Centre Régional de Lutte contre le cancer - Centre Georges-François Leclerc ( CRLCC - CGFL )
- Subjects
CD4-Positive T-Lymphocytes ,0301 basic medicine ,endocrine system diseases ,Cellular differentiation ,Melanoma, Experimental ,Regulator ,environment and public health ,[ SDV.CAN ] Life Sciences [q-bio]/Cancer ,STAT3 ,Mice ,Sirtuin 1 ,RAR-related orphan receptor gamma ,lcsh:QH301-705.5 ,Mice, Inbred BALB C ,biology ,Acetylation ,Cell Differentiation ,Nuclear Receptor Subfamily 1, Group F, Member 3 ,Metformin ,Cell biology ,Th17 ,RORγt ,medicine.symptom ,biological phenomena, cell phenomena, and immunity ,hormones, hormone substitutes, and hormone antagonists ,STAT3 Transcription Factor ,Agonist ,medicine.drug_class ,Transplantation, Heterologous ,Carbazoles ,Mice, Nude ,Inflammation ,[SDV.CAN]Life Sciences [q-bio]/Cancer ,Heterocyclic Compounds, 4 or More Rings ,General Biochemistry, Genetics and Molecular Biology ,03 medical and health sciences ,SIRT1 ,Cell Line, Tumor ,medicine ,Animals ,Humans ,cancer ,Molecular biology ,Mice, Inbred C57BL ,enzymes and coenzymes (carbohydrates) ,030104 developmental biology ,lcsh:Biology (General) ,biology.protein ,Th17 Cells - Abstract
International audience; Sirtuin-1 deacetylates proteins and has emerged as a critical regulator of different cellular processes, particularly inflammation. Basal SIRT1 activity was previously found to limit Th9 and enhance Th17 differentiation in mice, but the effect of pharmacological SIRT1 activation on T cell differentiation and antitumor responses remains unclear. Here, we find that SIRT1 pharmacological agonists selectively impede mouse and human Th17 cell differentiation. SIRT1 activation induces STAT3 deacetylation, thus reducing its ability to translocate into the nucleus, bind to Rorc promoter, and induce its transcription. SIRT1 agonists reduce tumor growth in mice by blocking Th17 cell differentiation. In cancer patients, the SIRT1 agonist metformin reduced the frequency of Th17 cells and STAT3 acetylation levels. Altogether, these data underscore that SIRT1 activation impedes Th17 cell differentiation and thereby limits tumor growth and suggest that SIRT1 activators may directly target IL-17A functions.
- Published
- 2017